|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings indicate that inhibition of HSP90 results in suppression of Src and its downstream effectors, including ERK, Akt, and NF-κB, and therefore that HSP90 inhibitors could be useful for treatment of MDR MM.
|
31650359 |
2020 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Blocking Hsp90 could enable effective antitumor effects in many tumor types, such as multiple myeloma and colon cancer.
|
31244417 |
2019 |
|
HSP90AA1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
KW-2478 is a novel non-ansamycin Hsp90 inhibitor with modest single-agent activity in relapsed/refractory myeloma but which shows synergistic antimyeloma activity with bortezomib (BTZ) in preclinical studies.
|
28873084 |
2017 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dendritic cells pulsed with HSPB1 and HSP90AA1 peptides were used to stimulate peripheral blood mononuclear cells from healthy volunteers and myeloma patients to generate HSP peptide-specific cytotoxic T lymphocytes (CTLs).
|
24824351 |
2014 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Short interfering RNA-mediated knockdown or pharmacological inhibition of Hsp72 and Hsp73 was performed to evaluate the role of these proteins in myeloma cell survival and for Hsp90-chaperone function.
|
23065523 |
2013 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to determine which signaling pathways that account for the differential sensitivity to the Hsp90-I 17DMAG on a panel of MM cell lines and freshly obtained MM cells.
|
23246572 |
2013 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cytotoxicity from HSP90 and CK2 targeting was present in a myeloma microenvironment model, on plasma cells from patients with myeloma and in an in vivo mouse xenograft model.
|
22351691 |
2012 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results suggest that the primary mechanisms by which apigenin kill MM cells is by targeting the trinity of CK2-Cdc37-Hsp90, and this observation reveals the therapeutic potential of apigenin in treating multiple myeloma.
|
21871133 |
2011 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
HuLuc63 triggered autologous ADCC against primary MM cells resistant to conventional or novel therapies, including bortezomib and HSP90 inhibitor; and pretreatment with conventional or novel anti-MM drugs markedly enhanced HuLuc63-induced MM cell lysis.
|
17906076 |
2008 |
|
HSP90AA1
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
These data suggest that targeted inhibition of HSP90 may prove to be a valid and innovative strategy for the development of future therapeutic options for MM patients.
|
16923571 |
2006 |